Product
Camrelizumab plus Famitinib
Name
Camrelizumab plus Famitinib
1 clinical trial
1 drug
1 indication
Indication
triple-negative breast cancerDrug
camrelizumabClinical trial
The Opportune Administration of Nab-paclitaxel in the First Line Treatment Strategy, Camrelizumab and Famitinib With/Without Nab-paclitaxel, of Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer:An Open, Single-arm, Multicenter Phase II Clinical Study.Status: Recruiting, Estimated PCD: 2023-09-01